Brian Overstreet

Brian Overstreet

Recent Posts

February 24, 2017

A Big Data Stumble in Healthcare

This week marked the annual HIMSS Conference.  HIMSS, Healthcare Information and Management Systems Society, is the big annual gathering of IT firms trying to market their wares into healthcare systems, pharmaceutical companies, and health insurers.

While usually a time for big partnerships, acquisitions, deployments, and new client wins, this year’s HIMSS kicked off in a rather inglorious manner.  On Sunday news broke that world-renowned cancer center MD Anderson had discontinued their partnership with IBM Watson.  After a string of big wins by the Watson team, this appeared to be the first – and certainly the largest – setback.

Read More
October 20, 2016

Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

faers_growth.pngSeventy two hours after 2016 Q2 FDA Adverse Event Reporting System (FAERS) data were publicly released by FDA, our RxFilter® process had it standardized and loaded into the Evidex platform.  Based on the volume of data in Q2, it looks like we’re well on the way to yet another record year of adverse events reported into FAERS. 

Here is a chart of new case reports (including our estimate for full year 2016).  Note that these numbers are based on a clean dataset; de-duplicated, primary suspect cases only).

Read More
July 15, 2016

Guest Post: BBK Talks #BigData with Advera Health Analytics

This post was originally published on the BBK Worldwide Blog.

Big Data was a Big Topic at this year’s DIA Annual Meeting, and continues to be an area of interest and investment across the life sciences and healthcare industries as organizations seek to further integrate new data streams and real-time analysis into clinical R&D. Data collection, management and analysis are at the crux of everything we do here at BBK, and our clients are keenly interested in how to manage and optimize Big Data. We interviewed Brian Overstreet, CEO of Advera Health Analytics, a leading healthcare informatics company, to get their take and to see how access to meaningful data is helping to push healthcare forward. 

Read More
July 8, 2016

Chronic Underreporting of Clinical Trials

Well, now we’re getting somewhere!

Read More
November 14, 2014

Should Adverse Drug Event Reporting by Healthcare Providers be Mandatory?

A recent article by Pharmacy Times titled, “Pharmacists Underreport Adverse Drug Reactions Due to Inadequate Training” made me really angry.

I’m angry at the pharmacists, I’m angry at FDA, I’m angry at the academic institutions, I’m angry at the whole damn system.

Why? – go read the article. Here’s the link again.

Indifference, insecurity, ignorance, guilt, fear, complacency, and lack of training. Those were the main factors the authors of the underlying study cited for why pharmacists fail to report adverse drug events. It’s like the 10 plagues on Passover, except worse.

Read More
October 2, 2014

FAERS - Myths vs. Realities


The use of the FDA’s Adverse Event Reporting System (FAERS) for broad post-approval drug safety studies has long been curtailed due to three assumed limitations of the dataset. AdverseEvents has systematically set out to debunk all three of these myths through the use of peer-reviewed studies in major academic journals. This blog article summarizes our findings and we invite you to review our complete journal articles for more details.


Read More
July 18, 2014

OpenFDA – the Good, the Bad, and the Ugly

On June 3rd, the FDA launched OpenFDA, in an attempt to take large internal datasets and make them more accessible and usable by the developer and business community.

OpenFDA is delivered in a search-based API that should enable software developers to more easily build applications based on adverse event data from the FDA Adverse Event Reporting System (FAERS) dataset for the period 1/1/2004 to 6/30/3013. The FDA has announced plans to add device and food adverse events data to the framework, along with structured product labeling and recall data (update: drug and device recall data was added on July 16). 

The launch was heralded with the sort of buzz and hoopla usually reserved for a major product launch from a Silicon Valley startup. I decided to hold off on any analysis and opinion until now to give our team the needed time to look through the system thoroughly.

Read More